Abstract
Treatments of obesity and type II diabetes target often gene functions involved in appetite-satiety, fat and carbohydrate metabolism or thermogenesis. None of these, have provided efficient drug therapy due to a large number of genes involved in weight and energy management, the redundancy of biochemical pathways and the environmental factors. Here I discuss a new approach based on studies of genes/proteins that are associated with human “lean or starvation" phenotype that became very rare in the course of evolution. This approach has led to the identification of the congenital enteropeptidase deficiency gene and the Andersonʼs Disease gene as a potential targets for obesity and type II diabetes treatment. The advantages of these targets are: 1) they are expressed exclusively in the intestine; 2) they are peripheral targets as opposed to systemic targets; 3) they are not redundant targets. These targets open new hopes for the development of novel drugs for the treatment of common metabolic syndrome.
Keywords: Diabetes treatment, drug discovery, lean phenotype, metabolic disorders, obesity, starvation phenotype, type II diabetes.
Current Pharmaceutical Biotechnology
Title:Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment
Volume: 14 Issue: 13
Author(s): Itzik Harosh
Affiliation:
Keywords: Diabetes treatment, drug discovery, lean phenotype, metabolic disorders, obesity, starvation phenotype, type II diabetes.
Abstract: Treatments of obesity and type II diabetes target often gene functions involved in appetite-satiety, fat and carbohydrate metabolism or thermogenesis. None of these, have provided efficient drug therapy due to a large number of genes involved in weight and energy management, the redundancy of biochemical pathways and the environmental factors. Here I discuss a new approach based on studies of genes/proteins that are associated with human “lean or starvation" phenotype that became very rare in the course of evolution. This approach has led to the identification of the congenital enteropeptidase deficiency gene and the Andersonʼs Disease gene as a potential targets for obesity and type II diabetes treatment. The advantages of these targets are: 1) they are expressed exclusively in the intestine; 2) they are peripheral targets as opposed to systemic targets; 3) they are not redundant targets. These targets open new hopes for the development of novel drugs for the treatment of common metabolic syndrome.
Export Options
About this article
Cite this article as:
Harosh Itzik, Rare Genetic Diseases with Human Lean and/or Starvation Phenotype Open New Avenues for Obesity and Type II Diabetes Treatment, Current Pharmaceutical Biotechnology 2013; 14 (13) . https://dx.doi.org/10.2174/1389201015666140408124559
DOI https://dx.doi.org/10.2174/1389201015666140408124559 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of the Active Constituents and Significant Pathways of Guizhi-Shaoyao-Zhimu Decoction for the Treatment of Diabetes Mellitus Based on Molecular Docking and Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds The Role Played by Serine Proteases in the Development and Worsening of Vascular Complications in Type 1 Diabetes Mellitus
Current Diabetes Reviews Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Platelet in Progression of Atherosclerosis: A Potential Target in Diabetic Patients
Current Diabetes Reviews Looking for New Inhibitors for the Epidermal Growth Factor Receptor
Current Topics in Medicinal Chemistry Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Lipid Disorders in Pregnancy
Current Pharmaceutical Design The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors
Current Drug Safety Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets Current Scenario of 1,4-Diazepines as Potent Biomolecules-A Mini Review
Mini-Reviews in Medicinal Chemistry